Know How Sparse Data AI Augments Pharmaceutical Processes
The implementation of sparse data AI bolsters the experimental results and provides accurate predictions regarding the behavior of molecules under specific conditions.
FREMONT, CA – The transition toward value-based healthcare has spurred the pharmaceutical industry to leverage emerging technologies such as artificial intelligence (AI) to improve predictive models in drug discovery and development. The big data fueled by the troves of information generated in R&D has facilitated valuable insights, leading to innovative healthcare approaches.
However, the introduction of sparse data AI has paved novel pathways for drug discovery and development. It has enabled the companies to form sophisticated biochemistry models backed by comprehensive explanation and inference. The incorporation of Artificial Intelligence has promoted higher transparency as well as productivity in the pharma industry.
In the pharmaceutical world, computational chemistry is used to predict convolute organic reactions and their outcomes. However, the conventional approaches to prediction are expensive as well as time-consuming. The new models are designed to create useful reaction sequences for selected target molecules. However, it is yet to be seen whether the models can form predictions outside the training data.
Organizations leverage big data to form flexible predictive models utilizing minimal domain knowledge. To predict the physiochemical properties of drug molecules, deep learning is often incorporated into big data. However, the last few years have witnessed a dramatic increase in the amount of available data due to the introduction of high-throughput screening and synthesis. Hence, it has become inevitable to incorporate AI to access vast datasets.
Bayesian Sparse Data Optimization
The applications of big data are limited since it utilizes algorithms without comprehending the underlying mechanisms involved in the model. The implementation of sparse data AI, on the other hand, can understand the references and offer better outcomes. It bolsters the experimental results with expert knowledge on the mechanism and provides accurate predictions regarding the behavior of molecules under specific conditions.
Incorporating Bayesian optimization to the sparse data AI enables the development of a sequential model-based approach. The process can be used to identify the optimal model, even with the presence of multiple unknowns. Sparse data AI has provided the pharmaceutical industry with the necessary tools to analyze vast troves of information and draw valuable insights. Hence, it is imperative for organizations to employ robust approaches in the different stages of drug discovery and development. It will not only introduce greater efficiency and productivity in the sector but will also help the patients to receive enhanced healthcare.
By Tom Farrah, CIO & SVP, Dr Pepper Snapple Group
By George Evans, CIO, Singing River Health System
By John Kamin, EVP and CIO, Old National Bancorp
By Phil Jordan, CIO, Telefonica
By Elliot Garbus, VP-IoT Solutions Group & GM-Automotive...
By Dennis Hodges, CIO, Inteva Products
By Bill Krivoshik, SVP & CIO, Time Warner Inc.
By Gregory Morrison, SVP & CIO, Cox Enterprises
By Alberto Ruocco, CIO, American Electric Power
By Sam Lamonica, CIO & VP Information Systems, Rosendin...
By Sven Gerjets, SVP-IT, DIRECTV
By Marie Blake, EVP & CCO, BankUnited
By Lowell Gilvin, Chief Process Officer, Jabil
By Walter Carvalho, VP & Corporate CIO, Carnival Corporation
By Mary Alice Annecharico, SVP & CIO, Henry Ford Health System
By Bernd Schlotter, President of Services, Unify
By Bob Fecteau, CIO, SAIC
By Jason Alan Snyder, CTO, Momentum Worldwide
By Jim Whitehurst, CEO, Red Hat
By Marc Jones, Distinguished Engineer, IBM Cloud Infrastructure